title: Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival.
abstract: Sophisticated surgical approaches have a definite but limited role in esophageal cancer. The majority have systemic disease at presentation, minimal residual disease following resection or co-morbid conditions that preclude extensive surgery. This paper examines whether neoadjuvant therapy is effective in advanced-stage disease. A randomized trial, closing September 1995, was followed up to determine results at 5 years. All patients were followed up for more than 5 years. Median survival, based on intention-to-treat, was 17 months for multimodal therapy vs. 12 months for surgery alone (P=0.002). Survival based on treatment received was 27 months vs. 14 months (P=0.0006). Multimodal therapy enhances survival for patients with minimal residual disease. This is consistent with the literature. Under-powered trials cannot prove a real difference to be significant. Future trials should target patients with minimal residual disease.
authors.affiliation: Royal College of Surgeons Department of Surgery, James Connolly Memorial Hospital, Blanchardstown, Dublin 15, Ireland. tnwalsh@indigo.ie
authors.forename: T N
authors.initials: TN
authors.lastname: Walsh
authors.forename: M
authors.initials: M
authors.lastname: Grennell
authors.forename: S
authors.initials: S
authors.lastname: Mansoor
authors.forename: A
authors.initials: A
authors.lastname: Kelly
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality* / Q000601:surgery*; D002299:Cardia; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000601:surgery*; D005500:Follow-Up Studies; D006801:Humans; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000401:mortality* / Q000601:surgery*; D016896:Treatment Outcome